Ellen Kim, MD @PennMedicine @PennCancer @skinlymphoma #Cu...

Ellen Kim, MD @PennMedicine @PennCancer @skinlymphoma #CutaneousLymphoma #Lymphoma #Cancer #Research Phase 3 FLASH Study Selected for Presentation at the USCLC
Cancer News Photo

Cancer News
1 साल 427 चेतावनी
वर्ग:
विवरण:

Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study speaks about the USCLC 2021 Abstract - HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting.

Link to Article:
https://www.prnewswire.com/news-releases/hybryte-positive-pivotal-phase-3-flash-study-selected-for-presentation-at-the-united-states-cutaneous-lymphoma-consortium-usclc-annual-meeting-301317045.html

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the study, has joined the company. Dr. Kim intends to discuss HyBryteTM's effectiveness in a broad CTCL patient group, as well as its safety and tolerability, and to compare the study's findings to presently available treatment alternatives. The FLASH trial, which enrolled 169 patients, is the biggest multicenter, randomized, double-blind, placebo-controlled, skin-directed treatment research in CTCL to date.